Join
Live feed
·
PRReleasevia Quantisnow
Ardelyx Inc. logo

Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

ByQuantisnow·Wall Street's wire, on your screen.
ARDX· Ardelyx Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARDX (Ardelyx Inc.) and more on Quantisnow.